Dan Leonard

I'm Dan Leonard, the life science tools and diagnostics analyst at RBC. And we're thrilled to have with us from Bio-Rad, Roop Lakkaraju, CFO; and Ruben Argueta from Investor Relations.

Thank you both for joining.

Roop Lakkaraju
Executive VP & CFO

Thanks for having us, Dan. Appreciate it.

Dan Leonard

So we've got some ground to cover and only 25 minutes to do it. I thought, Roop, to set the table, if you could just reflect back on your recently reported quarter, what worked, what were the challenges.

Roop Lakkaraju
Executive VP & CFO

Yes. We reported first quarter results at the end of April. Obviously, it's a dynamic environment, end markets continue to evolve. I think for us, maybe I'll highlight a few different things.

Number one, when I look at where our digital PCR instruments are, we had 24% year-over-year growth. We were very pleased with that. That's especially attributable to our QX700 series products, which are a result of the Stilla acquisition that we completed last year. The Stilla acquisition, upon acquiring them, we looked at getting to accretiveness within 18 to 24 months. We're actually ahead of that schedule. We kind of reiterated that within 12 months, we'll be accretive. So we're pleased with that.

And then when you look at some of the R&D improvements execution we've made, that's also reflected with our digital PCR platform. We were able to port 99% of our assays. We've got over 400,000 assays on digital PCR. Those were ported over ahead of time. So that just reinforces the value proposition of our QX700 platform. So that was very